CARM
Carisma Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−22.22%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 52.6M | 19.6M | 14.9M | 9.8M | 26.5M |
| Cost of Revenue | 2.6M | 59.7M | 74.1M | 6.1M | 85.0K |
| Gross Profit | 51.6M | (40.0M) | (59.2M) | 9.8M | 26.5M |
| Operating Expenses | |||||
| R&D Expense | 27.4M | 59.7M | 74.1M | 56.6M | 25.2M |
| SG&A Expense | 16.4M | 20.1M | 29.5M | 9.4M | 29.4M |
| General & Admin Expense | 14.4M | 20.1M | 29.5M | 9.4M | 6.4M |
| Selling & Marketing Expense | 1.9M | — | — | — | — |
| Other Expenses | (3.0M) | (57.7M) | (74.1M) | — | — |
| Total Operating Expenses | 40.8M | 22.1M | 29.5M | 66.0M | 54.6M |
| Cost and Expenses | 41.8M | 81.8M | 103.7M | 66.0M | 54.7M |
| Operating Income (EBIT) | 10.8M | (62.2M) | (88.7M) | (56.2M) | (28.2M) |
| Non-Operating | |||||
| Interest Income | 1.3M | 1.7M | 1.9M | — | 10.0K |
| Interest Expense | — | — | — | 3.1M | — |
| Net Interest Income | 1.3M | 1.7M | 1.9M | (3.1M) | 10.0K |
| Other Non-Op Income/Expense | (2.8M) | 1.7M | 1.9M | (5.1M) | 19.6M |
| Non-Operating Income (excl Interest) | (1.1M) | (2.0M) | — | 1.9M | (19.6M) |
| EBT (Pre-Tax Income) | 8.0M | (60.5M) | (86.9M) | (61.2M) | (8.6M) |
| Income Tax Expense | — | — | — | — | (8.3M) |
| Bottom Line | |||||
| Net Income | 8.0M | (60.5M) | (86.9M) | (61.2M) | (336.0K) |
| Earnings from Cont. Ops | 8.0M | (60.5M) | (86.9M) | (61.2M) | (336.0K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 8.0M | (60.5M) | (86.9M) | (61.2M) | (336.0K) |
| Per Share | |||||
| Basic EPS | $0.20 | ($1.46) | ($2.59) | ($1.52) | ($0.04) |
| Diluted EPS | $0.20 | ($1.46) | ($2.59) | ($1.52) | ($0.04) |
| Revenue Per Share | $1.26 | $0.47 | $0.45 | $0.24 | $2.91 |
| Shares | |||||
| Basic Shares Outstanding | 41.8M | 41.5M | 33.5M | 40.3M | 9.1M |
| Diluted Shares Outstanding | 41.9M | 41.5M | 33.5M | 40.3M | 9.1M |
| Profitability Metrics | |||||
| EBITDA | 13.7M | (56.8M) | (85.9M) | (56.2M) | (8.5M) |
| D&A | 1.7M | 3.4M | 2.8M | 1.9M | 85.0K |
| EBIT | 12.0M | (60.2M) | (88.7M) | (58.1M) | (8.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025